BullFrog AI Announces Positive Progress in Drug Discovery Program for Top 5 Global Pharmaceutical in Major Depressive Disorder
The program delivered identified and prioritized therapeutic targets for major depressive disorder using proprietary datasets.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BullFrog AI (BFRG) achieved project milestones in its commercial drug discovery program with a top 5 global pharmaceutical company. Its AI platform identified and prioritized novel therapeutic targets for major depressive disorder using proprietary biomedical datasets. The company views its first commercial project with a global pharmaceutical company as commercial-scale validation of its technology.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointCommercial project with a top 5 global pharmaceutical company achieved milestones and provided deliverables.
- Minor pointNovel therapeutic targets for major depressive disorder identified and prioritized using proprietary datasets.
- Minor point. Forward-looking: it has not happened yet and may not happen.Schizophrenia and bipolar disorder target discovery and development also form part of BullFrog AI's commercial strategy.
- Minor point. Forward-looking: it has not happened yet and may not happen.Other therapeutic areas offer opportunities to scale the technology, BullFrog AI believes.
Negative
- None.
Details
Market move: BFRG +8.01% vs previous close. MDD drug discovery progress
On Oct 6, the day this news came out, the latest delayed price for BFRG is 8.01% above the previous close. Argus tracked a peak move of +29.7% during the session. Argus tracked a trough of -15.9% from its starting point during tracking. Our momentum scanner has recorded 47 alerts for this stock so far that day. The latest delayed price is $0.64. Relative volume is exceptionally heavy at 4263.1x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Terms
major depressive disorder medical
multi-omic technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Achieves key commercial project milestones utilizing its proprietary artificial intelligence (“AI”) and machine learning platform to identify and prioritize therapeutic targets
GAITHERSBURG, Md., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), an AI company using its proprietary platform to turn complex biomedical data into actionable insights, announces it has achieved key project milestones under its commercial program with a top 5 global pharmaceutical company. BullFrog AI successfully identified and prioritized novel therapeutic targets for major depressive disorder (“MDD”) by applying its platform to proprietary neuropsychiatric multi-omic data sets.
“We’ve achieved important milestones and provided essential deliverables in our first commercial project with a global pharmaceutical company, identifying multiple novel and high-quality targets,” said BullFrog AI Founder and Chief Executive Officer Vin Singh. “We view this project as crucial commercial scale validation of our technology and believe our successes to date demonstrate the ability of our advanced AI and machine learning technologies to create high value assets.”
As a core component of its commercial strategy, BullFrog AI is also applying its technology to the discovery and development of novel drug targets for a range of other neuropsychiatric diseases, including schizophrenia and bipolar disorder. BullFrog AI believes there is significant opportunity to scale the application of its technology to other therapeutic areas of high patient impact through deep analysis of biomedical datasets.
About BullFrog AI
BullFrog AI harnesses artificial intelligence and machine learning to advance pharmaceutical R&D and drug target discovery, providing AI-accelerated outputs that are optimized and human-validated. BullFrog AI operates through three complementary capabilities, deployable independently or as a combined platform: bfPREP™ for biology-aware data harmonization, bfLEAP® for causal AI analytics and patient subgroup discovery, and bfARENAS™ for structured, auditable decision support. The common thread across all three: every output is traceable, every analytical decision is logged, and every recommendation is designed to be reviewed and validated by the scientific team before it drives a decision.
For more information visit BullFrog AI at: https://bullfrogai.com.
Safe Harbor Statement
This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Contact:
Investors:
CORE IR
ir@bullfrogai.com
Media:
pr@bullfrogai.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What milestones did BullFrog AI achieve in its major depressive disorder program?
BullFrog AI identified and prioritized novel therapeutic targets for major depressive disorder under its commercial program with a top 5 global pharmaceutical company. It applied its AI and machine learning platform to proprietary neuropsychiatric datasets containing multiple types of biological data.